KOD

Kodiak Sciences (KOD)

About Kodiak Sciences (KOD)

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Details

Daily high
$46.15
Daily low
$43.44
Price at open
--
52 Week High
$47.84
52 Week Low
$7.68
Market cap
2.7B
Dividend yield
0.00%
Volume
2
Avg. volume
592,689
P/E ratio
-10.45

Kodiak Sciences News

Details

Daily high
$46.15
Daily low
$43.44
Price at open
--
52 Week High
$47.84
52 Week Low
$7.68
Market cap
2.7B
Dividend yield
0.00%
Volume
2
Avg. volume
592,689
P/E ratio
-10.45